CA2900256C - Cd47 targeted therapies for the treatment of infectious disease - Google Patents
Cd47 targeted therapies for the treatment of infectious disease Download PDFInfo
- Publication number
- CA2900256C CA2900256C CA2900256A CA2900256A CA2900256C CA 2900256 C CA2900256 C CA 2900256C CA 2900256 A CA2900256 A CA 2900256A CA 2900256 A CA2900256 A CA 2900256A CA 2900256 C CA2900256 C CA 2900256C
- Authority
- CA
- Canada
- Prior art keywords
- sirpa
- virus
- cell
- cells
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Radiation-Therapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361761133P | 2013-02-05 | 2013-02-05 | |
| US61/761,133 | 2013-02-05 | ||
| PCT/US2014/014905 WO2014124028A1 (en) | 2013-02-05 | 2014-02-05 | Cd47 targeted therapies for the treatment of infectious disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2900256A1 CA2900256A1 (en) | 2014-08-14 |
| CA2900256C true CA2900256C (en) | 2023-03-21 |
Family
ID=51300110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2900256A Active CA2900256C (en) | 2013-02-05 | 2014-02-05 | Cd47 targeted therapies for the treatment of infectious disease |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US9771428B2 (pl) |
| EP (4) | EP3721888B1 (pl) |
| CA (1) | CA2900256C (pl) |
| DK (1) | DK3311824T3 (pl) |
| ES (4) | ES2983571T3 (pl) |
| HR (1) | HRP20200565T1 (pl) |
| PL (2) | PL3721888T3 (pl) |
| PT (1) | PT3721888T (pl) |
| SI (1) | SI3721888T1 (pl) |
| WO (1) | WO2014124028A1 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9771428B2 (en) * | 2013-02-05 | 2017-09-26 | The Board Of Trustees Of The Leland Stanford Junior University | CD47 targeted therapies for the treatment of infectious disease |
| ES2765483T3 (es) | 2013-09-18 | 2020-06-09 | Univ Leland Stanford Junior | Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica |
| ES2941387T3 (es) * | 2015-02-27 | 2023-05-22 | Univ Leland Stanford Junior | Terapia de combinación para el tratamiento de la ateroesclerosis |
| DK3298043T3 (da) * | 2015-05-18 | 2021-02-15 | Ab Initio Biotherapeutics Inc | SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse |
| US10259859B2 (en) | 2015-08-07 | 2019-04-16 | ALX Oncology Inc. | Constructs having a SIRP-α domain or variant thereof |
| CN106084052B (zh) * | 2016-06-17 | 2019-12-27 | 长春金赛药业股份有限公司 | 抗cd47单克隆抗体及其应用 |
| US12344669B2 (en) | 2016-06-17 | 2025-07-01 | Changchun Genescience Pharmaceutical Co., Ltd. | Anti-CD47 monoclonal antibody and use thereof |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| WO2018081448A1 (en) | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| US11779642B2 (en) | 2016-12-09 | 2023-10-10 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| WO2018124835A1 (ko) | 2016-12-29 | 2018-07-05 | 한국과학기술연구원 | 신규 엑소좀 계열 항암제 |
| WO2019022600A1 (en) * | 2017-07-24 | 2019-01-31 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47 |
| AU2018308364C1 (en) | 2017-07-26 | 2023-02-16 | Forty Seven, LLC | Anti-SIRP-alpha antibodies and related methods |
| EP3661965A4 (en) | 2017-08-02 | 2022-07-13 | Phanes Therapeutics, Inc. | ANTI-CD47 ANTIBODIES AND USES THEREOF |
| US11180552B2 (en) | 2017-12-01 | 2021-11-23 | Seagen Inc. | CD47 antibodies and uses thereof for treating cancer |
| US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
| GB201807945D0 (en) | 2018-05-16 | 2018-06-27 | Ospedale San Raffaele Srl | Vector production |
| JP7337099B2 (ja) | 2018-05-25 | 2023-09-01 | アレクトル エルエルシー | 抗ｓｉｒｐａ抗体およびその使用法 |
| AU2019349651B2 (en) | 2018-09-27 | 2023-12-07 | Celgene Corporation | SIRP alpha binding proteins and methods of use thereof |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020091596A1 (en) * | 2018-10-29 | 2020-05-07 | Umc Utrecht Holding B.V. | Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils |
| CN119700933A (zh) | 2019-05-31 | 2025-03-28 | Alx肿瘤生物技术公司 | 用SIRPαFc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| EP3756688A1 (en) | 2019-06-25 | 2020-12-30 | Université de Nantes | Inhibitor of surface protein (sp-d) / sirpa / shp2 pathway for use in the prevention and/or treatment of secondary infection |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| KR102690136B1 (ko) * | 2021-06-30 | 2024-07-31 | 연세대학교 산학협력단 | 바이러스 및 박테리아의 중복 감염 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995010265A1 (en) * | 1993-10-15 | 1995-04-20 | Cytrx Corporation | Therapeutic delivery compositions and methods of use thereof |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| EP2111869A1 (en) * | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| CA2761438C (en) | 2009-05-15 | 2017-12-12 | University Health Network | Compositions and methods for treating hematologic cancers targeting the sirp.alpha.-cd47 interaction |
| JP6166177B2 (ja) * | 2010-05-14 | 2017-07-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 |
| US9771428B2 (en) * | 2013-02-05 | 2017-09-26 | The Board Of Trustees Of The Leland Stanford Junior University | CD47 targeted therapies for the treatment of infectious disease |
-
2014
- 2014-02-05 US US14/763,758 patent/US9771428B2/en active Active
- 2014-02-05 ES ES22185801T patent/ES2983571T3/es active Active
- 2014-02-05 DK DK17194591.8T patent/DK3311824T3/da active
- 2014-02-05 SI SI201431994T patent/SI3721888T1/sl unknown
- 2014-02-05 CA CA2900256A patent/CA2900256C/en active Active
- 2014-02-05 ES ES17194591T patent/ES2794700T3/es active Active
- 2014-02-05 PL PL20163565.3T patent/PL3721888T3/pl unknown
- 2014-02-05 EP EP20163565.3A patent/EP3721888B1/en active Active
- 2014-02-05 PT PT201635653T patent/PT3721888T/pt unknown
- 2014-02-05 ES ES14748994.2T patent/ES2649165T3/es active Active
- 2014-02-05 EP EP22185801.2A patent/EP4119153B1/en active Active
- 2014-02-05 WO PCT/US2014/014905 patent/WO2014124028A1/en not_active Ceased
- 2014-02-05 PL PL22185801.2T patent/PL4119153T3/pl unknown
- 2014-02-05 EP EP17194591.8A patent/EP3311824B1/en active Active
- 2014-02-05 ES ES20163565T patent/ES2928001T3/es active Active
- 2014-02-05 EP EP14748994.2A patent/EP2953633B1/en active Active
-
2017
- 2017-08-14 US US15/676,296 patent/US10184004B2/en active Active
-
2018
- 2018-12-10 US US16/214,507 patent/US10723803B2/en active Active
-
2020
- 2020-04-07 HR HRP20200565TT patent/HRP20200565T1/hr unknown
- 2020-06-15 US US16/902,068 patent/US11230607B2/en active Active
-
2021
- 2021-12-14 US US17/550,881 patent/US11780931B2/en active Active
-
2023
- 2023-08-30 US US18/458,903 patent/US12410259B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12410259B2 (en) | CD47 targeted therapies for the treatment of infectious disease | |
| US20240181050A1 (en) | Agonist antibodies that bind human cd137 and uses thereof | |
| AU2014238105B2 (en) | Methods for achieving therapeutically effective doses of anti-CD47 agents | |
| US12286483B2 (en) | Method of treating cancer using CD137 antibodies and PD-1 antagonists | |
| HK40083909A (en) | Cd47 targeted therapies for the treatment of infectious disease | |
| HK40083909B (en) | Cd47 targeted therapies for the treatment of infectious disease | |
| US20220235131A1 (en) | Methods of treating infections by blocking pathogen mimics of cd47 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190104 |
|
| EEER | Examination request |
Effective date: 20190104 |
|
| EEER | Examination request |
Effective date: 20190104 |
|
| EEER | Examination request |
Effective date: 20190104 |
|
| EEER | Examination request |
Effective date: 20190104 |